Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.14 HKD | +1.14% | +2.02% | -24.30% |
May. 28 | China Grants Approval to Zhongsheng Pharma's Eye Drops | MT |
May. 21 | Zhongsheng Group Plans to Issue Up to 5 Billion Yuan Panda Bonds | MT |
Strengths
- Its low valuation, with P/E ratio at 6.39 and 5.6 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 0.24 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Auto Vehicles, Parts & Service Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.30% | 4.31B | B- | ||
+12.83% | 11.46B | B+ | ||
-13.40% | 10.52B | - | B | |
-5.24% | 10.17B | C+ | ||
+13.36% | 6.86B | B- | ||
+4.49% | 4.74B | C+ | ||
-10.28% | 3.5B | C | ||
-8.90% | 2.65B | - | ||
+17.90% | 2.01B | A | ||
+0.82% | 1.92B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 881 Stock
- Ratings Zhongsheng Group Holdings Limited